Cisbio Bioassays Marks Next Step in Development of Tag-lite™ GPCR Investigation Platform
News Sep 30, 2009
Cisbio Bioassays, a member of IBA group and global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services
used in assay development and drug screening, today announced that it has extended its Tag-lite™ cell surface receptor platform with the introduction of a comprehensive catalogue of ligands and plasmids.
The new catalogue marks the next step in the company’s development of a complete array of tools for G-Protein Coupled Receptor (GPCR) investigation and, more specifically, of Tag-lite, its homogeneous and non-radioactive
alternative for the study of cell surface receptor dimerization and ligand binding.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE